Allan Kermode
Overview
Explore the profile of Allan Kermode including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Brouwer E, Becker T, Werthen-Brabants L, Dewulf P, Iliadis D, Dekeyser C, et al.
PLOS Digit Health
. 2024 Jul;
3(7):e0000533.
PMID: 39052668
Background: Disability progression is a key milestone in the disease evolution of people with multiple sclerosis (PwMS). Prediction models of the probability of disability progression have not yet reached the...
2.
Learmonth Y, Bhoyroo R, Gibbs L, Kermode A, Walker D, Marck C
Mult Scler Relat Disord
. 2024 May;
87:105691.
PMID: 38781884
Background: Persons with multiple sclerosis (MS) need regular access to medical services for optimal health outcomes. During the COVID-19 crisis, evidence indicated some detrimental health changes in persons with MS....
3.
Huang Y, Luo W, Cheng X, Sun X, Wang Y, Shu Y, et al.
Mult Scler Relat Disord
. 2024 Jan;
82:105405.
PMID: 38194895
Background: There is an age-dependent change in the clinical phenotype of Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). However, the clinical features of late-onset MOGAD have not been well described. Methods:...
4.
Kalincik T, Sharmin S, Roos I, Freedman M, Atkins H, Burman J, et al.
JAMA Neurol
. 2023 Jul;
80(7):702-713.
PMID: 37437240
Importance: Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective: To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in...
5.
Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sanchez M, Ozakbas S, et al.
Brain
. 2023 Jun;
146(11):4633-4644.
PMID: 37369086
Geographical variations in the incidence and prevalence of multiple sclerosis have been reported globally. Latitude as a surrogate for exposure to ultraviolet radiation but also other lifestyle and environmental factors...
6.
Daruwalla C, Shaygannejad V, Ozakbas S, Kubala Havrdova E, Horakova D, Alroughani R, et al.
Mult Scler
. 2023 Feb;
29(7):875-883.
PMID: 36851894
Background: The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear. Objective: To determine whether early non-disabling relapses predict disability accumulation in RRMS. Methods: We...
7.
Abdul-Rahman A, Morgan W, Jo Khoo Y, Lind C, Kermode A, Carroll W, et al.
PLoS One
. 2022 Jun;
17(6):e0270557.
PMID: 35763528
Purpose: To compare the retinal vascular pulsatile characteristics in subjects with normal (ICPn) and high (ICPh) intracranial pressure and quantify the interactions between intraocular pressure, intracranial pressure, and retinal vascular...
8.
Sharmin S, Bovis F, Malpas C, Horakova D, Kubala Havrdova E, Izquierdo G, et al.
Eur J Neurol
. 2022 May;
29(8):2321-2334.
PMID: 35582938
Background And Purpose: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on...
9.
Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, et al.
Neurology
. 2020 Dec;
96(5):e783-e797.
PMID: 33372028
Objective: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. Methods: We studied patients from MSBase followed for...
10.
Learmonth Y, Chan Z, Correia H, Hathorn D, Kermode A, Smith C, et al.
Disabil Rehabil
. 2020 May;
43(25):3623-3638.
PMID: 32393076
Purpose: We undertook a qualitative study that explored exercise participation and exercise promotion in the multiple sclerosis (MS) community who live in regional or remote areas of Australia. By simultaneously...